Observational Study of the Use of octaplasLG .

  • participants needed
  • sponsor
Updated on 19 January 2021


This observational study enrolls patients who have received at least one infusion of octaplasLG. OctaplasLG will be administered standard of care and observation occurs during the treatment and 24 hours after the end of treatment. Characteristics of the use of octaplasLG, tolerance criteria, and efficacy criteria will be collected.


Prospective, non-interventional, multicentre study meeting a post-marketing need. The data will be collected in all patients who have received at least one infusion of octaplasLG.

The duration of follow-up is limited to the duration of treatment with octaplasLG plus 24 h of monitoring after cessation of treatment.

Characteristics of the use of octaplasLG (indication for the transfusion, degree of urgency, characteristics of plasma infusions, patient characteristics, number of iso-group and/or compatible units administered, tolerance criteria (adverse effects), and efficacy criteria (for patients with confirmed diagnosis of TTP--time to normalization of platelet count) will be collected.

Treatment OctaplasLG®
Clinical Study IdentifierNCT03369314
Last Modified on19 January 2021

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet